Progyny, Inc. (NASDAQ:PGNY) Stock Has Average Price Target of $34.36

Key Points

• Analysts maintain a “Moderate Buy” consensus on Progyny, with nine buy ratings, three holds and one strong buy. The average 12-month price target is $34.36, above the reported share price of $27.45.
• Progyny’s latest quarterly results exceeded expectations, with adjusted earnings of $0.55 per share versus the $0.33 consensus estimate and revenue of $350.51 million. Revenue increased 5.3% year over year, while the company issued fiscal 2026 EPS guidance of $2.04–$2.10.
• Institutional investors own approximately 94.93% of Progyny, while insiders hold 9.90%; recent insider activity included stock sales by an executive vice president and a director.

Shares of Progyny, Inc. (NASDAQ:PGNY - Get Free Report) have received an average recommendation of "Moderate Buy" from the thirteen research firms that are presently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $34.36.

Several analysts have recently weighed in on the company. Truist Financial upped their price objective on Progyny from $33.00 to $36.00 and gave the company a "buy" rating in a report on Thursday, August 13th. Jefferies Financial Group set a $33.00 price objective on shares of Progyny in a research note on Tuesday, September 8th. JPMorgan Chase & Co. boosted their target price on shares of Progyny from $27.00 to $30.00 and gave the stock a "neutral" rating in a report on Friday, August 21st. Barclays decreased their price target on shares of Progyny from $34.00 to $30.00 and set an "equal weight" rating on the stock in a research report on Wednesday, August 12th. Finally, Wells Fargo & Company started coverage on Progyny in a research report on Wednesday, September 30th. They set an "overweight" rating and a $37.00 price objective for the company.

Insiders Place Their Bets

In related news, EVP Allison Swartz sold 3,903 shares of the company's stock in a transaction that occurred on Wednesday, September 23rd. The shares were sold at an average price of $26.10, for a total value of $101,868.30. Following the completion of the sale, the executive vice president owned 75,816 shares in the company, valued at approximately $1,978,797.60. This represents a 4.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin K. Gordon sold 11,500 shares of the company's stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $27.94, for a total transaction of $321,310.00. Following the completion of the sale, the director owned 6,792 shares of the company's stock, valued at approximately $189,768.48. This trade represents a 62.87% decrease in their position. The SEC filing for this sale provides additional information. 9.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Toth Financial Advisory Corp lifted its position in Progyny by 21.3% in the 3rd quarter. Toth Financial Advisory Corp now owns 2,735 shares of the company's stock worth $69,000 after buying an additional 480 shares in the last quarter. WINTON GROUP Ltd boosted its position in Progyny by 266.7% during the second quarter. WINTON GROUP Ltd now owns 251,834 shares of the company's stock valued at $7,260,000 after purchasing an additional 183,163 shares during the last quarter. Engineers Gate Manager LP boosted its position in Progyny by 5.6% during the second quarter. Engineers Gate Manager LP now owns 152,757 shares of the company's stock valued at $4,404,000 after purchasing an additional 8,156 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new position in Progyny in the second quarter valued at about $74,000. Finally, IFP Advisors Inc grew its stake in Progyny by 376.0% in the second quarter. IFP Advisors Inc now owns 1,961 shares of the company's stock valued at $57,000 after purchasing an additional 1,549 shares in the last quarter. 94.93% of the stock is owned by institutional investors and hedge funds.

Progyny Price Performance

NASDAQ PGNY opened at $27.45 on Friday. Progyny has a 12 month low of $16.10 and a 12 month high of $33.06. The firm has a market capitalization of $2.11 billion, a PE ratio of 29.84, a P/E/G ratio of 1.92 and a beta of 1.02. The company's 50 day simple moving average is $26.43 and its 200 day simple moving average is $25.45.

Progyny (NASDAQ:PGNY - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share for the quarter, topping analysts' consensus estimates of $0.33 by $0.22. The firm had revenue of $350.51 million during the quarter, compared to the consensus estimate of $349.05 million. Progyny had a return on equity of 15.98% and a net margin of 6.00%. The firm's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.19 earnings per share. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Sell-side analysts anticipate that Progyny will post 1.25 earnings per share for the current fiscal year.

About Progyny

Progyny, Inc NASDAQ: PGNY is a fertility and family-building benefits company that helps employers provide reproductive health services to their employees. Its platform is designed to support individuals and families navigating fertility treatment, preservation, adoption, surrogacy and related family-building needs.

The company offers an integrated benefits solution that combines personalized care navigation with access to a network of fertility specialists and treatment providers. Progyny also provides pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.